Description: New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2013 and is headquartered in Hangzhou, China.
Home Page: ir.newhorizonbio.com
T1 Building
Hangzhou,
310052
China
Phone:
86 57 1811 07210
Officers
| Name | Title |
|---|---|
| Mr. Yeqing Zhu | CEO, Exec. Chairman & Co-founder |
| Mr. Yu Gao | CFO & Joint Company Sec. |
| Dr. Ning Lu | Chief Technology Officer |
| Dr. Yiyou Chen Ph.D. | Exec. Director & Chief Scientific Officer |
| Ms. Ming-Wai Mok | Joint Company Sec. |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 98.7097 |
| Price-to-Book MRQ: | 3.6491 |
| Price-to-Sales TTM: | 18.8027 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 861 |